1 / 44

Diagnosis and Management of Alzheimer s Disease

Dementia. DefinitionDomains of dementiaEpidemiologyCausesPathology of dementiasTreatmentEvolving directions. Definition of Dementia. Dementia (DSM-IV). Memory impairmentImpairment in one other cognitive domain (aphasia, apraxia, agnosia, executive dysfunction)Acquired (not presented througho

spencer
Download Presentation

Diagnosis and Management of Alzheimer s Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. Diagnosis and Management of Alzheimer’s Disease Jeffrey Cummings, MD Mary S. Easton Center for Alzheimer’s Disease Research Deane F. Johnson Center for Neurotherapeutics David Geffen School of Medicine at UCLA Los Angeles, California, USA

    2. Dementia Definition Domains of dementia Epidemiology Causes Pathology of dementias Treatment Evolving directions

    3. Definition of Dementia

    4. Dementia (DSM-IV) Memory impairment Impairment in one other cognitive domain (aphasia, apraxia, agnosia, executive dysfunction) Acquired (not presented throughout life) Disabling (occupational, social) Not present only during delirium Not attributable to a primary psychiatric illness (e.g., major depression, schizophrenia, etc)

    5. Dementia is Recognized by Mental Status Examination Attention (impaired in delirium) Digit span Concentration Memory impairment Orientation (time, place) 3 word learning test with delayed recall

    6. Dementia is Recognized by Mental Status Examination Language Spontaneous speech Naming Comprehension (1,2,3 step command) Repetition Visuospatial skills Copy figures (overlapping pentagons, cube) Draw a clock Executive function Judgment, insight Word list generation (animals named per minute)

    7. Dementia is Recognized by Mental Status Examination Mini-Mental Status Examination (MMSE) Montreal Cognitive Assessment (MoCA) Neuropsychological assessment Dementia is under-recognized Assumed to be normal aging No mental status examination done

    8. Domains of Dementia

    9. Domains of Dementia

    10. Domains of Dementia

    11. AD is a Progressive, Fatal Illness

    12. Epidemiology of Dementia

    13. Epidemiology of Dementia

    14. Epidemiology of Dementia US 5.5 million Alzheimer’s disease patients 2030 – 7.8 million AD patients $148 billion now $1 trillion annually by 2050 Global 35 million AD patients 2-30 – 65 million AD patients

    15. Risk and Protective Factors Risk factors Age ApoE-4 genotype Female gender Hypertension, elevated cholesterol Head trauma Protective factors Education Exercise Mental activity

    16. Causes of Dementia

    17. Causes of Dementia Alzheimer’s disease (55-70% of late-onset dementia) Vascular dementia Parkinson’s disease with dementia and related disorders Dementia with Lewy bodies (DLB) Pathology of Parkinson’s disease and Alzheimer’s disease Frontotemporal dementia (FTD) Misc: trauma, alcohol, B12 deficiency, hypothyroidism, HIV, etc

    18. Evaluation of Dementia to Determine Its Cause History Current symptoms Past history and treatments Family history Laboratory tests B12 level Thyroid stimulating hormone (TSH) CBC, electrolytes, , blood sugar, BUN, liver function tests Brain imaging MRI or CT

    19. Approaching the Differential Diagnosis of Dementia

    20. Diagnosis of Alzheimer’s Disease Memory impairment Impairment in one other cognitive domain (aphasia, apraxia, agnosia, executive dysfunction) Acquired (not presented throughout life) Disabling (occupational, social) Gradually progressive Not present only during delirium Not attributable to a primary psychiatric illness or other cause of dementia

    21. Pathology of Dementias

    22. Pathology of Dementias Alzheimer’s disease Brain atrophy Neuritic plaques Amyloid beta protein Neurofibrillary tangles Hyperphosphorylated tau protein Loss of nerve cells

    23. Brain Atrophy in Alzheimer’s Disease

    24. Histopathology of Alzheimer’s Disease

    26. Pathology of Dementias Vascular dementia Ischemic white matter lesions Small infarctions in basal ganglia, thalamus, white matter Large infarctions

    27. Pathology of Dementias Dementia with Lewy bodies (DLB) and PD dementia Alpha-synuclein Lewy bodies in brainstem, cortex Limited AD-type pathology in most Frontotemporal dementia Tau protein inclusions TDP-43 protein inclusions Other

    28. Pathology of Dementias

    29. Treatment of Dementias

    30. Treatment of Alzheimer’s Disease Cholinesterase inhibitors (ChE-Is) Donepezil (Aricept) Rivastigmine (Exelon) Galantamine (Razadyne) NMDA receptor antagonist Memantine (Namenda)

    31. Treatment of Alzheimer’s Disease Symptomatic effects Mild improvement and delay of decline Cognition Function (activities of daily living) Behavior Global measures

    32. Treatment of Alzheimer’s Disease Many patients are treated (off label) with psychotropic agents Antidepressants Atypical antipsychotics Care of the caregiver is an important aspect of patient management

    33. Treatment of Alzheimer’s Disease Side effects Cholinesterase inhibitors Diarrhea Nausea, vomiting Memantine Headache Dizziness Somnolence

    34. Treatment of Non-AD Dementias

    35. Evolving Research Directions

    36. Mild Cognitive Impairment (MCI) Dementias are preceded by states of mild cognitive impairment Memory impairment without functional loss Not all MCI progresses to dementia Some are stable in MCI state Some improve Some progress to AD (60% of MCI) Some progress to non-AD dementias

    37. New Criteria Allow Diagnosis of AD before Dementia Memory impairment Progressive Not attributable to another cause (e.g., hypothyrodism) Biomarker evidence of AD as the cause of the “MCI” Medial temporal atrophy on MRI Parietal hypometabolism on FDG PET (bilateral) Positive amyloid imaging CSF with low amyloid and high tau/p-tau levels

    38. MRI Demonstrates Brain Atrophy in Early Alzheimer’s Disease Hippocampal atrophy emphasized in this slideHippocampal atrophy emphasized in this slide

    40. Amyloid Imaging Shows Deposition of Amyloid in Plaques

    41. Disease-Modifying Therapies are Evolving for Alzheimer’s Disease Anti-amyloid therapies Gamma secretase inhibitors (decrease production) Aggregation inhibitors (prevent toxicity) Immunotherapies (passive; vaccination)(remove deposits) Tau-related therapies Neuroprotective agents Latreperdine/dimebon Anti-oxidants

    44. Summary

    45. Summary Dementia is common among the elderly and growing in frequency Dementia requires memory loss, loss in another cognitive domain and functional impairment Dementia has many causes Alzheimer’s disease is the most common cause of dementia AD is treated with cholinesterase inhibitors and memantine

More Related